Dongsung Pharm (002210) — Cash Flow-to-Debt Ratio
Dongsung Pharm (002210) has a Cash Flow-to-Debt Ratio of 0.04x as of June 2025, meaning its operating cash flow of ₩4.20 Billion could theoretically repay 0% of its total liabilities (₩107.40 Billion) in one year. See Dongsung Pharm free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Dongsung Pharm Cash Flow-to-Debt Ratio (2008–2024)
Historical debt coverage capacity for Dongsung Pharm across 13 annual periods. Also explore net asset momentum of Dongsung Pharm to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Dongsung Pharm (2008–2024)
Year-by-year debt coverage analysis for Dongsung Pharm. For market capitalisation and broader financial context, see Dongsung Pharm stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.10x | ₩-9.94 Billion | ₩96.73 Billion | ▼ -80.0% |
| 2023 | -0.06x | ₩-4.29 Billion | ₩75.17 Billion | ▲ +4.5% |
| 2022 | -0.06x | ₩-3.88 Billion | ₩64.89 Billion | ▼ -26.4% |
| 2021 | -0.05x | ₩-2.75 Billion | ₩58.14 Billion | ▼ -166.9% |
| 2020 | 0.07x | ₩5.01 Billion | ₩70.77 Billion | ▲ +152.5% |
| 2019 | -0.13x | ₩-8.31 Billion | ₩61.63 Billion | ▼ -900.0% |
| 2018 | 0.02x | ₩1.39 Billion | ₩82.71 Billion | ▼ -43.9% |
| 2017 | 0.03x | ₩1.80 Billion | ₩59.91 Billion | ▲ +162.6% |
| 2016 | -0.05x | ₩-3.34 Billion | ₩69.77 Billion | ▼ -16.7% |
| 2011 | -0.04x | ₩-2.64 Billion | ₩64.38 Billion | ▼ -176.6% |
| 2010 | 0.05x | ₩3.68 Billion | ₩68.71 Billion | ▲ +164.0% |
| 2009 | -0.08x | ₩-5.02 Billion | ₩59.94 Billion | ▼ -1201.5% |
| 2008 | -0.01x | ₩-365.26 Million | ₩56.75 Billion | — |